{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T13:43:56Z","timestamp":1768225436827,"version":"3.49.0"},"reference-count":102,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH\/NIAID","award":["AI125626"],"award-info":[{"award-number":["AI125626"]}]},{"name":"NIH\/NIAID","award":["AI128556"],"award-info":[{"award-number":["AI128556"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Mammarenaviruses (MaAv) cause persistent infection in their natural rodent hosts across the world and, via zoonotic events, can cause severe disease in humans. Thus, the MaAv Lassa virus (LASV) in Western Africa and the Junin virus (JUNV) in the Argentinean Pampas cause hemorrhagic fever diseases with significant case fatality rates in their endemic regions. In addition, the globally distributed MaAv lymphocytic choriomeningitis virus (LCMV) is an underrecognized human pathogen of clinical significance capable of causing devastating infections in neonates and immunocompromised individuals. Despite their impact on human health, there are currently no FDA-approved vaccines or specific antiviral treatments for MaAv infections. Existing anti-MaAv therapies are limited to the off-label use of ribavirin, whose efficacy remains controversial; hence, the development of novel therapeutics to combat human pathogenic MaAv is vital. We employed a high-throughput cell-based infection assay to screen the Pandemic Response Box, a collection of 400 diverse compounds with established antimicrobial activity, for MaAv inhibitors. We identified Ro-24-7429, an antagonist of the HIV-1 Tat protein and RUNX family transcription factor 1 inhibitor; WO 2006118607 A2, a dihydroorotate dehydrogenase inhibitor; and verdinexor, a novel selective inhibitor of nuclear export (SINE) targeting the XPO1\/CRM1, as potent anti-MaAv compounds. Consistent with their distinct validated targets, verdinexor and WO 2006118607 A2 exhibited very strong synergistic antiviral activity when used in combination therapy. Our findings pave the way for the development of verdinexor as a potent host-directed antiviral against MaAv, which could be integrated into the development of combination therapy with direct- or host-acting antivirals to combat human pathogenic MaAv.<\/jats:p>","DOI":"10.3390\/v18010103","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T10:25:23Z","timestamp":1768213523000},"page":"103","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Screening of the Pandemic Response Box Library Identified CRM1\/XPO1 as an Anti-Mammarenavirus Druggable Target"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0664-9698","authenticated-orcid":false,"given":"Chukwudi A.","family":"Ofodile","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology and Public Health, Faculty of Medical Laboratory Science, Nnamdi Azikiwe University, Awka 435102, Nigeria"},{"name":"Department of Immunology and Microbiology, Scripps Research Institute, San Diego, CA 92037, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8048-410X","authenticated-orcid":false,"given":"Beatrice","family":"Cubitt","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbiology, Scripps Research Institute, San Diego, CA 92037, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ngozi","family":"Onyemelukwe","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Sciences, Faculty of Health Sciences and Technology, University of Nigeria, Nsukka 400001, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4125-7155","authenticated-orcid":false,"given":"Chetachi B.","family":"Okwuanaso","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Public Health, Faculty of Medical Laboratory Science, Nnamdi Azikiwe University, Awka 435102, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0174-8454","authenticated-orcid":false,"given":"Haydar","family":"Witwit","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbiology, Scripps Research Institute, San Diego, CA 92037, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8171-8115","authenticated-orcid":false,"given":"Juan C.","family":"de la Torre","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbiology, Scripps Research Institute, San Diego, CA 92037, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"ref_1","unstructured":"Knipe, D.M., and Whelan, S.P.J. (2021). Arenaviridae: The Viruses and Their Replication. Fields Virology: Emerging Viruses, Lippincott Williams & Wilkins. [7th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1038\/s41591-024-03232-y","article-title":"Health and Economic Impacts of Lassa Vaccination Campaigns in West Africa","volume":"30","author":"Smith","year":"2024","journal-title":"Nat. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41579-022-00789-8","article-title":"Lassa Fever\u2014The Road Ahead","volume":"21","author":"Garry","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Fichet-Calvet, E., and Rogers, D.J. (2009). Risk Maps of Lassa Fever in West Africa. PLoS Neglected Trop. Dis., 3.","DOI":"10.1371\/journal.pntd.0000388"},{"key":"ref_5","first-page":"165","article-title":"Lassa Fever Natural History and Clinical Management","volume":"Volume 440","author":"Grant","year":"2023","journal-title":"Lassa Fever: Epidemiology, Immunology, Diagnostics, and Therapeutics"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Basinski, A.J., Fichet-Calvet, E., Sjodin, A.R., Varrelman, T.J., Remien, C.H., Layman, N.C., Bird, B.H., Wolking, D.J., Monagin, C., and Ghersi, B.M. (2021). Bridging the Gap: Using Reservoir Ecology and Human Serosurveys to Estimate Lassa Virus Spillover in West Africa. PLoS Comput. Biol., 17.","DOI":"10.1371\/journal.pcbi.1008811"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S359","DOI":"10.1093\/infdis\/jiac266","article-title":"The Arenaviridae Family: Knowledge Gaps, Animal Models, Countermeasures, and Prototype Pathogens","volume":"228","author":"Hastie","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e696","DOI":"10.1016\/S1473-3099(24)00229-9","article-title":"Lassa Fever Research Priorities: Towards Effective Medical Countermeasures by the End of the Decade","volume":"24","author":"Moore","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e830","DOI":"10.1093\/infdis\/jiaf308","article-title":"Serosurveillance Identifies an Endemic Hotspot of Lassa Fever in Faranah, Upper Guinea","volume":"232","author":"Nuismer","year":"2025","journal-title":"J. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ijid.2022.02.020","article-title":"A Challenging Response to a Lassa Fever Outbreak in a Non Endemic Area of Sierra Leone in 2019 with Export of Cases to The Netherlands","volume":"117","author":"Njuguna","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1863-2378.2012.01469.x","article-title":"Lassa Fever in West Africa: Evidence for an Expanded Region of Endemicity","volume":"59","author":"Sogoba","year":"2012","journal-title":"Zoonoses Public Health"},{"key":"ref_12","first-page":"865","article-title":"Emerging Infectious Diseases and Risk to the Traveler","volume":"83","author":"Freedman","year":"1999","journal-title":"Med. Clin. N. Am."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1086\/322620","article-title":"Viral Hemorrhagic Fever Hazards for Travelers in Africa","volume":"33","author":"Steffen","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e2002324118","DOI":"10.1073\/pnas.2002324118","article-title":"Ranking the Risk of Animal-to-Human Spillover for Newly Discovered Viruses","volume":"118","author":"Grange","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.1038\/s41467-022-33112-3","article-title":"Predicting the Evolution of the Lassa Virus Endemic Area and Population at Risk over the next Decades","volume":"13","author":"Klitting","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_16","unstructured":"(2025, March 10). Prioritizing Diseases for Research and Development in Emergency Contexts. Available online: https:\/\/www.who.int\/activities\/prioritizing-diseases-for-research-and-development-in-emergency-contexts."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"0008","DOI":"10.1079\/cabionehealth.2025.0008","article-title":"A One Health Approach for South American Hemorrhagic Fevers","volume":"4","author":"Wilson","year":"2025","journal-title":"CABI One Health"},{"key":"ref_18","unstructured":"(2025, December 25). Congenital Lymphocytic Choriomeningitis Virus: Prenatal Diagnosis. Available online: https:\/\/www.ovid.com\/journals\/pred\/fulltext\/10.1002\/pd.6192~congenital-lymphocytic-choriomeningitis-virus-a-review."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1056\/NEJMoa073785","article-title":"A New Arenavirus in a Cluster of Fatal Transplant-Associated Diseases","volume":"358","author":"Palacios","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4149\/av_2013_02_160","article-title":"Lymphocytic Choriomeningitis Virus: Invisible but Not Innocent","volume":"57","year":"2013","journal-title":"Acta Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2542250","DOI":"10.1080\/22221751.2025.2542250","article-title":"Discovery of a Novel Lymphocytic Choriomeningitis Virus Strain Associated with Severe Human Disease in Immunocompetent Patient, New Mexico","volume":"14","author":"Gass","year":"2025","journal-title":"Emerg. Microbes Infect."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s40506-015-0058-0","article-title":"Treatment of Arenavirus Infections","volume":"7","author":"Schieffelin","year":"2015","journal-title":"Curr. Treat. Options Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Salam, A.P., Cheng, V., Edwards, T., Olliaro, P., Sterne, J., and Horby, P. (2021). Time to Reconsider the Role of Ribavirin in Lassa Fever. PLoS Neglected Trop. Dis., 15.","DOI":"10.1371\/journal.pntd.0009522"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"14775","DOI":"10.1038\/srep14775","article-title":"The Broad-Spectrum Antiviral Favipiravir Protects Guinea Pigs from Lethal Lassa Virus Infection Post-Disease Onset","volume":"5","author":"Safronetz","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a Broad Spectrum Inhibitor of Viral RNA Polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Jpn. Acad. Ser. B"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e00951-22","DOI":"10.1128\/aac.00951-22","article-title":"Safety and Pharmacokinetics of LHF-535, a Potential Treatment for Lassa Fever, in Healthy Adults","volume":"66","author":"Amberg","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"105125","DOI":"10.1016\/j.antiviral.2021.105125","article-title":"Potent Inhibition of Arenavirus Infection by a Novel Fusion Inhibitor","volume":"193","author":"Gowen","year":"2021","journal-title":"Antivir. Res."},{"key":"ref_28","unstructured":"Probechem Biochemicals (2025, September 25). ARN-75039|Arenavirus Inhibitor. Available online: https:\/\/www.probechem.com\/products_ARN-75039.html."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3201\/eid2409.180233","article-title":"Use of Favipiravir to Treat Lassa Virus Infection in Macaques","volume":"24","author":"Rosenke","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"\u0141agocka, R., Dziedziejko, V., K\u0142os, P., and Pawlik, A. (2021). Favipiravir in Therapy of Viral Infections. J. Clin. Med., 10.","DOI":"10.3390\/jcm10020273"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.12688\/f1000research.16989.1","article-title":"Lassa Virus Diversity and Feasibility for Universal Prophylactic Vaccine","volume":"8","author":"Lukashevich","year":"2019","journal-title":"F1000Research"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.cell.2015.07.020","article-title":"Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus","volume":"162","author":"Andersen","year":"2015","journal-title":"Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"993","DOI":"10.15212\/ZOONOSES-2024-0051","article-title":"Functional Characterization of a Lassa Virus Fusion Inhibitor Adaptive Mutant","volume":"5","author":"Guo","year":"2025","journal-title":"Zoonoses"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s13238-018-0604-x","article-title":"Structure-Activity Relationship Optimization for Lassa Virus Fusion Inhibitors Targeting the Transmembrane Domain of GP2","volume":"10","author":"Zhang","year":"2019","journal-title":"Protein Cell"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Garry, R. (2023). Lassa Virus Structural Biology and Replication. Lassa Fever: Epidemiology, Immunology, Diagnostics, and Therapeutics, Springer International Publishing.","DOI":"10.1007\/978-3-031-35807-4"},{"key":"ref_36","first-page":"23","article-title":"Lassa Virus Genetics","volume":"Volume 440","author":"Klitting","year":"2023","journal-title":"Lassa Fever: Epidemiology, Immunology, Diagnostics, and Therapeutics"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Radoshitzky, S.R., and de la Torre, J.C. (2019). Human Pathogenic Arenaviruses (Arenaviridae). Encyclopedia of Virology, Elsevier.","DOI":"10.1016\/B978-0-12-814515-9.00014-X"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Salvato, M.S. (2018). Assays to Assess Arenaviral Glycoprotein Function. Hemorrhagic Fever Viruses: Methods and Protocols, Springer.","DOI":"10.1007\/978-1-4939-6981-4"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug Repurposing: Progress, Challenges and Recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Ofodile, C.A., Uzochukwu, I.C., Ezebuo, F.C., Ejiofor, I., Adebola, M., Okpoli, I., Cubitt, B., Witwit, H., Okwuanaso, C.B., and Onyemelukwe, N. (2025). Flunarizine as a Candidate for Drug Repurposing Against Human Pathogenic Mammarenaviruses. Viruses, 17.","DOI":"10.3390\/v17010117"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Felciano, R.M., Bavari, S., Richards, D.R., Billaud, J.-N., Warren, T., Panchal, R., and Kr\u00e4mer, A. (2013, January 3\u20137). Predictive systems biology APPROACH to broad-spectrum, host-directed drug target discovery in infectious diseases. Proceedings of the Biocomputing 2013, Kohala Coast, HI, USA.","DOI":"10.1142\/9789814447973_0003"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1021\/ci4005354","article-title":"Pathway Analysis for Drug Repositioning Based on Public Database Mining","volume":"54","author":"Pan","year":"2014","journal-title":"J. Chem. Inf. Model."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Jamir, E., Sarma, H., Priyadarsinee, L., Kiewhuo, K., Nagamani, S., and Sastry, G.N. (2023). Polypharmacology Guided Drug Repositioning Approach for SARS-CoV2. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0289890"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1021\/acsinfecdis.1c00527","article-title":"The Pandemic Response Box\u2014Accelerating Drug Discovery Efforts after Disease Outbreaks","volume":"8","author":"Samby","year":"2022","journal-title":"ACS Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1128\/jvi.68.1.25-33.1994","article-title":"Inhibition of Human Immunodeficiency Virus Type 1 Tat-Dependent Activation of Translation in Xenopus Oocytes by the Benzodiazepine Ro24-7429 Requires Trans-Activation Response Element Loop Sequences","volume":"68","author":"Braddock","year":"1994","journal-title":"J. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1128\/jvi.69.4.2640-2643.1995","article-title":"The Human Immunodeficiency Virus Type 1 Tat Antagonist, Ro 5-3335, Predominantly Inhibits Transcription Initiation from the Viral Promoter","volume":"69","author":"Cupelli","year":"1995","journal-title":"J. Virol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1093\/infdis\/172.5.1246","article-title":"A Randomized Trial of the Activity and Safety of Ro 24-7429 (Tat Antagonist) versus Nucleoside for Human Immunodeficiency Virus Infection","volume":"172","author":"Haubrich","year":"1995","journal-title":"J. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ajpath.2021.04.006","article-title":"Targeting Runt-Related Transcription Factor 1 Prevents Pulmonary Fibrosis and Reduces Expression of Severe Acute Respiratory Syndrome Coronavirus 2 Host Mediators","volume":"191","author":"Amarnani","year":"2021","journal-title":"Am. J. Pathol."},{"key":"ref_49","unstructured":"Bennett, C.E., Byrd, J.C., Elgamal, O.A., Goodwin, T.E., Hertlein, E., Johnson, M.L., Tridandapani, S., and Vibhute, S.M. (2025, November 02). Methods and Compositions for Inhibition of Dihydroorotate Dehydrogenase in Combination with an Anti-CD38 Therapeutic Agent. AU2020412805A1, Available online: https:\/\/patents.google.com\/patent\/AU2020412805A1\/en."},{"key":"ref_50","unstructured":"Gudmundsson, K., and Samano, V. (2025, November 02). Hcv Inhibitors with Carbazole Structure. WO2006118607A3, Available online: https:\/\/patents.google.com\/patent\/WO2006118607A3\/en."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/vco.12680","article-title":"The Selective Inhibitor of Nuclear Export (SINE) Verdinexor Exhibits Biologic Activity against Canine Osteosarcoma Cell Lines","volume":"19","author":"Breitbach","year":"2021","journal-title":"Vet. Comp. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"10228","DOI":"10.1128\/JVI.01774-14","article-title":"Verdinexor, a Novel Selective Inhibitor of Nuclear Export, Reduces Influenza A Virus Replication In Vitro and In Vivo","volume":"88","author":"Perwitasari","year":"2014","journal-title":"J. Virol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"19223","DOI":"10.1038\/s41598-021-98767-2","article-title":"Reversible Disruption of XPO1-Mediated Nuclear Export Inhibits Respiratory Syncytial Virus (RSV) Replication","volume":"11","author":"Mathew","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Perwitasari, O., Johnson, S., Yan, X., Register, E., Crabtree, J., Gabbard, J., Howerth, E., Shacham, S., Carlson, R., and Tamir, S. (2016). Antiviral Efficacy of Verdinexor In Vivo in Two Animal Models of Influenza A Virus Infection. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0167221"},{"key":"ref_55","first-page":"51","article-title":"Viruses as Quasispecies: Biological Implications","volume":"Volume 299","author":"Domingo","year":"2006","journal-title":"Quasispecies: Concept and Implications for Virology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"41660","DOI":"10.1038\/srep41660","article-title":"Baseline Quasispecies Selection and Novel Mutations Contribute to Emerging Resistance-Associated Substitutions in Hepatitis C Virus after Direct-Acting Antiviral Treatment","volume":"7","author":"Kai","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1021\/acsinfecdis.7b00236","article-title":"Mining a Kr\u00f6hnke Pyridine Library for Anti-Arenavirus Activity","volume":"4","author":"Miranda","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1128\/JVI.02229-10","article-title":"Use of Single-Cycle Infectious Lymphocytic Choriomeningitis Virus to Study Hemorrhagic Fever Arenaviruses","volume":"85","author":"Rodrigo","year":"2011","journal-title":"J. Virol."},{"key":"ref_59","first-page":"6","article-title":"Quantification of Lymphocytic Choriomeningitis Virus with an Immunological Focus Assay in 24 Well Plates","volume":"10","author":"Battegay","year":"1993","journal-title":"ALTEX\u2014Altern. Anim. Exp."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e01883-23","DOI":"10.1128\/jvi.01883-23","article-title":"Activation of Protein Kinase Receptor (PKR) Plays a pro-Viral Role in Mammarenavirus-Infected Cells","volume":"98","author":"Witwit","year":"2024","journal-title":"J. Virol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.virol.2008.09.008","article-title":"A Cell-Based Luciferase Assay Amenable to High-Throughput Screening of Inhibitors of Arenavirus Budding","volume":"382","author":"Capul","year":"2008","journal-title":"Virology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"104667","DOI":"10.1016\/j.antiviral.2019.104667","article-title":"A Cell-Based, Infectious-Free, Platform to Identify Inhibitors of Lassa Virus Ribonucleoprotein (vRNP) Activity","volume":"173","author":"Cubitt","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e02256-17","DOI":"10.1128\/JVI.02256-17","article-title":"A Highly Conserved Leucine in Mammarenavirus Matrix Z Protein Is Required for Z Interaction with the Virus L Polymerase and Z Stability in Cells Harboring an Active Viral Ribonucleoprotein","volume":"92","author":"Iwasaki","year":"2018","journal-title":"J. Virol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genom. Proteom. Bioinform."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for Drug Synergy in Complex Dose\u2013Response Landscapes Using an Interaction Potency Model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"104558","DOI":"10.1016\/j.antiviral.2019.104558","article-title":"The ReFRAME Library as a Comprehensive Drug Repurposing Library to Identify Mammarenavirus Inhibitors","volume":"169","author":"Kim","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"12978","DOI":"10.1073\/pnas.2133782100","article-title":"The Small RING Finger Protein Z Drives Arenavirus Budding: Implications for Antiviral Strategies","volume":"100","author":"Perez","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"12651","DOI":"10.1128\/JVI.01012-09","article-title":"The Z Protein of the New World Arenavirus Tacaribe Virus Has Bona Fide Budding Activity That Does Not Depend on Known Late Domain Motifs","volume":"83","author":"Urata","year":"2009","journal-title":"J. Virol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e01684-18","DOI":"10.1128\/JVI.01684-18","article-title":"Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication In Vitro","volume":"93","author":"Jorquera","year":"2019","journal-title":"J. Virol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"001891","DOI":"10.1099\/jgv.0.001891","article-title":"ICTV Virus Taxonomy Profile: Arenaviridae 2023","volume":"104","author":"Radoshitzky","year":"2023","journal-title":"J. Gen. Virol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Liao, Y., Ke, X., Deng, T., and Qin, Q. (2021). The Second-Generation XPO1 Inhibitor Eltanexor Inhibits Human Cytomegalovirus (HCMV) Replication and Promotes Type I Interferon Response. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.675112"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41419-020-03303-1","article-title":"Targeting XPO1 Enhances Innate Immune Response and Inhibits KSHV Lytic Replication during Primary Infection by Nuclear Stabilization of the P62 Autophagy Adaptor Protein","volume":"12","author":"Meng","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"105115","DOI":"10.1016\/j.antiviral.2021.105115","article-title":"Selinexor, a Novel Selective Inhibitor of Nuclear Export, Reduces SARS-CoV-2 Infection and Protects the Respiratory System in Vivo","volume":"192","author":"Kashyap","year":"2021","journal-title":"Antivir. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"9452","DOI":"10.1128\/JVI.00155-10","article-title":"Induction and Inhibition of Type I Interferon Responses by Distinct Components of Lymphocytic Choriomeningitis Virus","volume":"84","author":"Zhou","year":"2010","journal-title":"J. Virol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Witwit, H., Cubitt, B., Khafaji, R., Castro, E.M., Goicoechea, M., Lorenzo, M.M., Blasco, R., Martinez-Sobrido, L., and de la Torre, J.C. (2025). Repurposing Drugs for Synergistic Combination Therapies to Counteract Monkeypox Virus Tecovirimat Resistance. Viruses, 17.","DOI":"10.3390\/v17010092"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1086\/657315","article-title":"Review of the Literature and Proposed Guidelines for the Use of Oral Ribavirin as Postexposure Prophylaxis for Lassa Fever","volume":"51","author":"Bausch","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug Repositioning: Identifying and Developing New Uses for Existing Drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Lochaiyakun, N., Srimanote, P., Khantisitthiporn, O., and Thanongsaksrikul, J. (2024). Novel Anti-Enterovirus A71 Compounds Discovered by Repositioning Antivirals from the Open-Source MMV Pandemic Response Box. Pharmaceuticals, 17.","DOI":"10.3390\/ph17060785"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"105990","DOI":"10.1016\/j.antiviral.2024.105990","article-title":"Discovery of a Small-Molecule Inhibitor of KSHV Lytic Replication from the MMV Pandemic Response Box","volume":"230","author":"Okpara","year":"2024","journal-title":"Antivir. Res."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Holwerda, M., V\u2019kovski, P., Wider, M., Thiel, V., and Dijkman, R. (2020). Identification of an Antiviral Compound from the Pandemic Response Box That Efficiently Inhibits SARS-CoV-2 Infection In Vitro. Microorganisms, 8.","DOI":"10.1101\/2020.05.17.100404"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"42711","DOI":"10.1021\/acsomega.5c04858","article-title":"Screening of Medicines for Malaria Venture Open Boxes Identifies Potent SARS-CoV-2 Papain-like Protease (PLpro) Inhibitors","volume":"10","author":"Gawriljuk","year":"2025","journal-title":"ACS Omega"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"105294","DOI":"10.1016\/j.antiviral.2022.105294","article-title":"Identification of Novel Ebola Virus Inhibitors Using Biologically Contained Virus","volume":"200","author":"Vanmechelen","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00284-024-03874-8","article-title":"New Highly Selective Antivirals for Chikungunya Virus Identified from the Screening of a Drug-Like Compound Library","volume":"81","author":"Castro","year":"2024","journal-title":"Curr. Microbiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"198388","DOI":"10.1016\/j.virusres.2021.198388","article-title":"Discovery of an Imidazonaphthyridine and a Riminophenazine as Potent Anti-Zika Virus Agents through a Replicon-Based High-Throughput Screening","volume":"299","author":"Fernandes","year":"2021","journal-title":"Virus Res."},{"key":"ref_85","unstructured":"(2025, November 03). Ro 24-7429. Available online: https:\/\/go.drugbank.com\/drugs\/DB16062."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2008.12.015","article-title":"GSK983: A Novel Compound with Broad-Spectrum Antiviral Activity","volume":"82","author":"Harvey","year":"2009","journal-title":"Antivir. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.chembiol.2020.05.002","article-title":"Enhancing the Antiviral Efficacy of RNA-Dependent RNA Polymerase Inhibition by Combination with Modulators of Pyrimidine Metabolism","volume":"27","author":"Liu","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Kim, Y.-J., Cubitt, B., Cai, Y., Kuhn, J.H., Vitt, D., Kohlhof, H., and de la Torre, J.C. (2020). Novel Dihydroorotate Dehydrogenase Inhibitors with Potent Interferon-Independent Antiviral Activity against Mammarenaviruses In Vitro. Viruses, 12.","DOI":"10.3390\/v12080821"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Widman, D.G., Gornisiewicz, S., Shacham, S., and Tamir, S. (2018). In Vitro Toxicity and Efficacy of Verdinexor, an Exportin 1 Inhibitor, on Opportunistic Viruses Affecting Immunocompromised Individuals. PLoS ONE, 13.","DOI":"10.1101\/351825"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.tips.2024.11.002","article-title":"Therapeutic Targeting of Exportin-1 beyond Nuclear Export","volume":"46","author":"Chen","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/S1473-3099(16)00078-5","article-title":"Host-Directed Therapies for Infectious Diseases: Current Status, Recent Progress, and Future Prospects","volume":"16","author":"Zumla","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e00168-19","DOI":"10.1128\/CMR.00168-19","article-title":"Host-Directed Antiviral Therapy","volume":"33","author":"Kumar","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM199709113371102","article-title":"Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy","volume":"337","author":"Gulick","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_94","unstructured":"NIH (2025, November 05). FDA-Approved HIV Medicines, Available online: https:\/\/hivinfo.nih.gov\/understanding-hiv\/fact-sheets\/fda-approved-hiv-medicines."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Sever, B., Otsuka, M., Fujita, M., and Ciftci, H. (2024). A Review of FDA-Approved Anti-HIV-1 Drugs, Anti-Gag Compounds, and Potential Strategies for HIV-1 Eradication. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202401.1357.v1"},{"key":"ref_96","unstructured":"(2025, July 13). Treatment of Chronic Hepatitis C Virus Infection in Adults\u2014Clinical Guidelines Program. Available online: https:\/\/www.hivguidelines.org\/guideline\/hcv-treatment\/."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"91ra63","DOI":"10.1126\/scitranslmed.3002304","article-title":"A Critical Subset Model Provides a Conceptual Basis for the High Antiviral Activity of Major HIV Drugs","volume":"3","author":"Shen","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm1777","article-title":"Dose-Response Curve Slope Sets Class-Specific Limits on Inhibitory Potential of Anti-HIV Drugs","volume":"14","author":"Shen","year":"2008","journal-title":"Nat. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.coph.2019.07.006","article-title":"Improving Therapy of Severe Infections through Drug Repurposing of Synergistic Combinations","volume":"48","author":"Cheng","year":"2019","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nbt.1549","article-title":"Synergistic Drug Combinations Tend to Improve Therapeutically Relevant Selectivity","volume":"27","author":"Krueger","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e1684","DOI":"10.1002\/ctm2.1684","article-title":"The Nuclear Export Protein Exportin-1 in Solid Malignant Tumours: From Biology to Clinical Trials","volume":"14","author":"Lai","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"London, C.A., Bernabe, L.F., Barnard, S., Kisseberth, W.C., Borgatti, A., Henson, M., Wilson, H., Jensen, K., Ito, D., and Modiano, J.F. (2014). Preclinical Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Spontaneous Canine Cancer: Results of a Phase I Study. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087585"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/1\/103\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T10:34:46Z","timestamp":1768214086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/1\/103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":102,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["v18010103"],"URL":"https:\/\/doi.org\/10.3390\/v18010103","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]}}}